Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, Vladimir J.N., Issaeva, Natalia, Shilov, Alexandre, Hultcrantz, Monica, Pugacheva, Elena, Chumakov, Peter, Bergman, Jan, Wiman, Klas G. +1 more·2002·Nature Medicine
DOI 10.1038/nm0302-282

Cited by (1,000)

Items 201–300 of 1,000

  1. Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases
    Ya‐Xiong Tao, P. Michael Conn · 2018 · Physiological Reviews
  2. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
    Donkena Krishna Vanaja, Karla V. Ballman, Bruce W. Morlan, John C. Cheville, Roxann M. Neumann, Michael M. Lieber, Donald J. Tindall, Charles Y.F. Young · 2006 · Clinical Cancer Research
  3. Pathologies Associated with the p53 Response
    Andrei V. Gudkov, Elena A. Komarova · 2010 · Cold Spring Harbor Perspectives in Biology
  4. Senescent Cells and Their Secretory Phenotype as Targets for Cancer Therapy
    Velarde, Michael C., Demaria, Marco, Campisi, Judith · 2013 · Interdisciplinary Topics in Gerontology and Geriatrics
  5. Regulators of Oncogenic Mutant TP53 Gain of Function
    Satomi Yamamoto, Tomoo Iwakuma · 2018 · Cancers
  6. The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise
    Anna Mandinova, Sam W. Lee · 2011 · Science Translational Medicine
  7. p53 and its downstream proteins as molecular targets of cancer
    Yi Sun · 2006 · Molecular Carcinogenesis
  8. Targeting p53 by small molecules in hematological malignancies
    Manujendra N. Saha, Lugui Qiu, Hong Hee Chang · 2013 · Journal of Hematology & Oncology
  9. Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?
    Naoise C. Synnott, A. Murray, Patricia M. McGowan, M. Kiely, Patrick A. Kiely, Norma O’Donovan, Darran P. O’Connor, William M. Gallagher, John Paul Crown, Michael Joe Duffy · 2016 · International Journal of Cancer
  10. Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm
    Kalliopi Tsafou, Purushottam Babu Tiwari, Julie Deborah Forman-Kay, Steven J. Metallo, Jeffrey A. Toretsky · 2018 · Journal of Molecular Biology
  11. p53 isoform Δ113p53/Δ133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage
    Lu Gong, Hongjian Gong, Xiao Pan, Changqing Chang, Zhao Ou, Shengfan Ye, Le Yin, Lina Yang, Ting Tao, Zhenhai Zhang et al. · 2015 · Cell Research
  12. The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
    Maurice Stephan Michel, Leonard Kaps, Annett Maderer, Peter R. Galle, Markus Hermann Moehler · 2021 · Cancers
  13. Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions
    Altaf A. Dar, Alexander I. Zaika, Maria Blanca Piazuelo, Pelayo Correa, Tatsuki Koyama, Abbes Belkhiri, Kay M. Washington, Antoni Castells, Manuel Pera, Wael M. El-Rifai · 2008 · Cancer
  14. Genetic abnormalities and pathophysiology of MDS
    Naoko Hosono · 2019 · International Journal of Clinical Oncology
  15. Anti-Apoptosis Mechanisms in Malignant Gliomas
    David Simon Ziegler, Andrew L. Kung, Mark W. Kieran · 2008 · Journal of Clinical Oncology
  16. Apoptotic Pathways and Therapy Resistance in Human Malignancies
    Kristina Viktorsson, Rolf Lewensohn, Boris Zhivotovsky · 2005 · Advances in cancer research
  17. Targeting tumor suppressor genes for cancer therapy
    Yunhua Liu, Xiaoxiao Hu, Cecil Han, Liana Wang, Xinna Zhang, Xiaoming He, Xiongbin Lu · 2015 · BioEssays
  18. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion
    Sachin Mehta, Kent W. Christopherson, Poornima Bhat‐Nakshatri, Robert J. Goulet, Hal E. Broxmeyer, Levy Kopelovich, Harikrishna Nakshatri · 2006 · Oncogene
  19. The eIF2α Kinases PERK and PKR Activate Glycogen Synthase Kinase 3 to Promote the Proteasomal Degradation of p53
    Baltzis, Dionissios, Pluquet, Olivier, Papadakis, Andreas I., Kazemi, Shirin, Qu, Li-Ke, Koromilas, Antonis E. · 2007 · Journal of Biological Chemistry
  20. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis
    Lasse Weinmann, Jörg Wischhusen, Mark J. Demma, Ulrike Naumann, Patrick Roth, Bimalendu Dasmahapatra, Michael Weller · 2008 · Cell Death and Differentiation
  21. SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53
    Mark J. Demma, Eugene Maxwell, Robert Ramos, Lianzhu Liang, Cheng Li, David Hesk, Randall R. Rossman, Alan K. Mallams, Ronald J. Doll, Ming Liu et al. · 2010 · Journal of Biological Chemistry
  22. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53
    Shengliang Zhang, Lanlan Zhou, Bo Hong, A. Pieter J. van den Heuvel, Varun V. Prabhu, Noel A. Warfel, Christina Leah B. Kline, David T. Dicker, Levy Kopelovich, Wafik S. El‐Deiry · 2015 · Cancer Research
  23. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis
    J M R Lambert, Ali Moshfegh, Pierre L. Hainaut, Klas G. Wiman, Vladimir J.N. Bykov · 2009 · Oncogene
  24. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
    Ramona Schulz‐Heddergott, Ute Martha Moll · 2018 · Cancers
  25. An N-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells
    Mohammad B. Uddin, Kartik R. Roy, Salman B. Hosain, Sachin Khiste, Ronald A. Hill, Seetharama D. S. Jois, Yunfeng Zhao, Alan J. Tackett, Yu Liu · 2018 · Biochemical Pharmacology
  26. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways
    J Cheng, Y-H Fan, Xin Yi Xu, Hanwen Zhang, J Dou, Ying Fei Tang, Xiangyu Zhong, Yesenia Rojas, Yang Yu, Yanling Zhao et al. · 2014 · Cell Death and Disease
  27. Restoration of p53 to limit tumor growth
    Wenge Wang, Wafik S. El‐Deiry · 2008 · Current Opinion in Oncology
  28. Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction
    Fujihara, Kenji M., Zhang, Bonnie Z., Jackson, Thomas D., Ogunkola, Moses O., Nijagal, Brunda, Milne, Julia V., Sallman, David A., Ang, Ching-Seng, Nikolic, Iva, Kearney, Conor J. et al. · 2022 · Science Advances
  29. Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth
    Aggarwal, M, Saxena, R, Sinclair, E, Fu, Y, Jacobs, A, Dyba, M, Wang, X, Cruz, I, Berry, D, Kallakury, B et al. · 2016 · Cell Death & Differentiation
  30. Aberrant phase separation and cancer
    Kenzui Taniue, Nobuyoshi Akimitsu · 2021 · FEBS Journal
  31. Strategies for targeting undruggable targets
    Gong Zhang, Juan Zhang, Yuting Gao, Yangfeng Li, Yizhou Li · 2021 · Expert Opinion on Drug Discovery
  32. Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer.
    Yolanda Olmos, J. Brosens, E. Lam · 2011 · Drug resistance updates
  33. PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
    Manujendra N. Saha, Hua Jiang, Yijun Yang, Donna Ellen Reece, Hong Chang · 2013 · Molecular Cancer Therapeutics
  34. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.
    Simon A. Williams, David James McConkey · 2003 · PubMed
  35. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
    Sharmila Patel, Mark R. Player · 2008 · Expert Opinion on Investigational Drugs
  36. Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic Agents
    Karita Peltonen, Laureen C. Colis, Hester Liu, Sari Jäämaa, Henna M. Moore, Juulia Enbäck, Pirjo Maarit Laakkonen, Anne Vaahtokari, Richard John Jones, Taija M. af Hällström et al. · 2010 · PLoS ONE
  37. NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity
    QiJiong Li, Xiaofeng Liu, Kemin Jin, Min Lu, Chunfeng Zhang, Xiaojuan Du, Baocai Xing · 2017 · BMC Cancer
  38. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53
    Elizabeth Alli, J-M Yang, William N. Hait · 2006 · Oncogene
  39. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors
    Hui Li, Jinglin Zhang, JOANNA H.M. TONG, Anthony W.H. Chan, Jun Qing Yu, Wei Kang, Ka Fai To · 2019 · International Journal of Molecular Sciences
  40. Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
    Bin Song, Ping Yang, Shuyu Zhang · 2024 · 癌症：英文版
  41. Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition
    Zhen Wang, Min Zheng, Zhichuan Frank Li, Ruiguo Li, Lijun Jia, Xiufang Xiong, Noel T Southall, Shaomeng Wang, Menghang Xia, Christopher P. Austin et al. · 2009 · Cancer Research
  42. Do Mutations Turn p53 into an Oncogene?
    Consuelo Pitolli, Ying Wang, Mara Mancini, Yufang Shi, Gerry Melino, Ivano Amelio · 2019 · International Journal of Molecular Sciences
  43. Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer
    Taylor P Berke, Simon H. Slight, Salman M Hyder · 2022 · OncoTargets and Therapy
  44. Regulation of Programmed Cell Death by the P53 Pathway
    Kageaki Kuribayashi, Wafik S. El‐Deiry · 2007 · Advances in experimental medicine and biology
  45. p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?
    Aime A. Levesque, Alan R. Eastman · 2006 · Carcinogenesis
  46. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma
    David S H Liu, Matthew D. Read, Carleen M. Cullinane, Walid J. Azar, Christina M. Fennell, Karen G. Montgomery, Sue Haupt, Ygal Haupt, Klas G. Wiman, Cuong P Duong et al. · 2015 · Gut
  47. Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells
    Yong Weon Yi, Hyo Jin Kang, Hee Jeong Kim, Yali Kong, Milton L. Brown, Insoo Bae · 2013 · Oncotarget
  48. p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma
    Jong‐Lyel Roh, Sung Koo Kang, Il Minn, Joseph A. Califano, David Sidransky, Wayne M. Koch · 2010 · Oral Oncology
  49. Identification of ANKRD11 as a p53 coactivator
    Paul Matthew Neilsen, Kelly M. Cheney, Chia-Wei Li, J. Don Chen, Jacqueline E. Cawrse, Renèe B. Schulz, Jason A. Powell, Raman Kumar, David Frederick Callen · 2008 · Journal of Cell Science
  50. A global suppressor motif for p53 cancer mutants
    Timothy E. Baroni, Ting Wang, Qian Hua, Lawrence R. Dearth, Lan N. Truong, Jue Zeng, Alec E. Denes, Stephanie W. Chen, Rainer Karl Brachmann · 2004 · Proceedings of the National Academy of Sciences
  51. The p53 circuit board
    Kelly D. Sullivan, Corrie L. Gallant‐Behm, Ryan E. Henry, Jean-Luc Fraikin, Joaquin Maximiliano Espinosa · 2012 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  52. Mutant p53: One, No One, and One Hundred Thousand
    Dawid Walerych, Kamil Lisek, Giannino Del Sal · 2015 · Frontiers in Oncology
  53. Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
    Paola Monti, Paola Menichini, Andrea Speciale, Giovanna Cutrona, Franco Fais, Elisa Taìana, Antonino Neri, Riccardo Bomben, Massimo Gentile, Valter Gattei et al. · 2020 · Frontiers in Oncology
  54. TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)
    Maria Lina Tornesello · 2024 · International Journal of Molecular Medicine
  55. Identification of potential synthetic lethal genes to p53 using a computational biology approach
    Xiaosheng Wang, Richard Simon · 2013 · BMC Medical Genomics
  56. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells
    Luciana Pereira Rangel, Giulia D. S. Ferretti, Caroline L. Costa, Sarah M.M.V. Andrade, Renato Sampaio Carvalho, Danielly C. Ferraz da Costa, Jerson Lima Silva · 2019 · Journal of Biological Chemistry
  57. G-protein-coupled OX1 Orexin/hcrtr-1 Hypocretin Receptors Induce Caspase-dependent and -independent Cell Death through p38 Mitogen-/Stress-activated Protein Kinase
    Sylwia Ammoun, Dan Lindholm, Hanna Wootz, Karl E.O. Åkerman, Jyrki P. Kukkonen · 2005 · Journal of Biological Chemistry
  58. Progestin-Dependent Progression of Human Breast Tumor Xenografts: A Novel Model for Evaluating Antitumor Therapeutics
    Yayun Liang, Cynthia L Besch-Williford, Rolf A. Brekken, Salman M. Hyder · 2007 · Cancer Research
  59. Restoration of wild‐type p53 function in human cancer: Relevance for tumor therapy
    Gianluca Bossi, Ada Sacchi · 2007 · Head & Neck
  60. Targeting Biomolecular Condensation and Protein Aggregation against Cancer
    Jerson Lima Silva, Débora Foguel, Vı́tor F. Ferreira, Tuane C. R. G. Vieira, Mayra A. Marques, Giulia D. S. Ferretti, Tiago F. Outeiro, Yraima Cordeiro, Guilherme A. P. de Oliveira · 2023 · Chemical Reviews
  61. An open-label phase I dose-finding study of APR-246 in hematological malignancies
    Deneberg, S, Cherif, H, Lazarevic, V, Andersson, P-O, von Euler, M, Juliusson, G, Lehmann, S · 2016 · Blood Cancer Journal
  62. Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases
    Simone Barreto Siqueira Parrilha Terra, Jin Sung Jang, Lintao Bi, Benjamin R. Kipp, Jin Jen, Eunhee S. Yi, Jennifer M. Boland · 2016 · Modern Pathology
  63. Unraveling the Guardian: p53’s Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies
    Han Zhang, Jianxiong Xu, Yuxuan Long, Ayitila Maimaitijiang, Zhengding Su, Wenfang Li, Jinyao Li · 2024 · International Journal of Molecular Sciences
  64. Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations
    Julianne S. Funk, Maria Klimovich, Daniel Drangenstein, Ole Pielhoop, Pascal Hunold, Anna Borowek, Maxim Noeparast, Evangelos Pavlakis, Michelle M. Neumann, Dimitrios-Ilias Balourdas et al. · 2025 · Nature Genetics
  65. TRAIL combinations: The new ‘trail’ for cancer therapy (Review)
    Alaa Refaat, Ahmed Abdrabou, Asmaa M. Reda · 2014 · Oncology Letters
  66. Small molecule agents targeting the p53‐MDM2 pathway for cancer therapy
    Weisi Wang, Yongzhou Hu · 2011 · Medicinal Research Reviews
  67. Drug discovery and p53
    David Philip Lane, Ted R. Hupp · 2003 · Drug Discovery Today
  68. p53 as a target for anti-cancer drug development
    Benjamin Pierre Bouchet, Claude Caron de Fromentel, Alain Puisieux, Carlos María Galmarini · 2006 · Critical Reviews in Oncology/Hematology
  69. Targeting p53-MDM2-MDMX Loop for Cancer Therapy
    Qi Zhang, Shelya X. Zeng, Hua Lu · 2014 · Sub-cellular biochemistry/Subcellular biochemistry
  70. p53 and retinoblastoma pathways in bladder cancer
    Anirban Pradip Mitra, Marc Birkhahn, Richard J. Côté · 2007 · World Journal of Urology
  71. Exploiting tumor cell senescence in anticancer therapy
    Minyoung Lee, Jae‐Seon Lee · 2014 · BMB Reports
  72. The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer?
    David E. Moulder, Diana Hatoum, Enoch S. E. Tay, Yiguang Lin, Eileen M. McGowan · 2018 · Cancers
  73. Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
    Gabriel LaPlante, Wei Zhang · 2021 · Cancers
  74. Pharmacological reactivation of p53 as a strategy to treat cancer
    Zawacka‐Pankau, J., Selivanova, G. · 2015 · Journal of Internal Medicine
  75. Hepatocellular Carcinoma
    Lynne W. Elmore, Xin Wei Wang, Curtis C. Harris · 2006 · Encyclopedia of Life Sciences
  76. Regulation of Metabolic Activity by p53
    Flöter, Jessica, Kaymak, Irem, Schulze, Almut · 2017 · Metabolites
  77. Therapeutic targeting of p53 by small molecules
    Galina Selivanova · 2010 · Seminars in Cancer Biology
  78. Molecularly targeted therapies for p53-mutant cancers
    Dekuang Zhao, William M. Tahaney, Abhijit Mazumdar, Michelle I. Savage, Powel H. Brown · 2017 · Cellular and Molecular Life Sciences
  79. Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis
    Hiraki, Masatsugu, Hwang, So-Young, Cao, Shugeng, Ramadhar, Timothy R., Byun, Sanguine, Yoon, Kyoung Wan, Lee, Jung Hyun, Chu, Kiki, Gurkar, Aditi U., Kolev, Vihren et al. · 2015 · Chemistry & Biology
  80. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ)
    Degtjarik, Oksana, Golovenko, Dmitrij, Diskin-Posner, Yael, Abrahmsén, Lars, Rozenberg, Haim, Shakked, Zippora · 2021 · Nature Communications
  81. Reviving the guardian of the genome: Small molecule activators of p53
    Daniel Nguyen, Wenjuan Liao, Shelya X. Zeng, Hua Lu · 2017 · Pharmacology & Therapeutics
  82. Dysregulation of Glucose Metabolism by Oncogenes and Tumor Suppressors in Cancer Cells
    Casterland Marbaniang, Lakhan Kma · 2018 · Europe PMC (PubMed Central)
  83. Targeting apoptosis pathways in glioblastoma
    Günter Eisele, Michael Weller · 2011 · Cancer Letters
  84. p53 family proteins in thyroid cancer
    Roberta Malaguarnera, Veronica Vella, Riccardo Vigneri, Francesco Frasca · 2007 · Endocrine Related Cancer
  85. Overview of the clinical efficacy of investigational anticancer drugs
    Peter Nygren, Rolf L. Larsson · 2003 · Journal of Internal Medicine
  86. Restoring p53-mediated apoptosis in cancer cells: New opportunities for cancer therapy
    Qiang Yu · 2006 · Drug Resistance Updates
  87. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA
    Zhao, Carolyn Y., Grinkevich, Vera, Nikulenkov, Fedor, Bao, Wenjie, Selivanova, Galina · 2010 · Cell Cycle
  88. Translational approaches targeting the p53 pathway for anti‐cancer therapy
    Essmann, Frank, Schulze‐Osthoff, Klaus · 2012 · British Journal of Pharmacology
  89. Tumor suppressor p53: from engaging DNA to target gene regulation
    Morgan A. Sammons, Thuy‐Ai Nguyen, Simon S. McDade, Martin Fischer · 2020 · Nucleic Acids Research
  90. An inverse docking approach for identifying new potential anti-cancer targets
    Sam Z. Grinter, Yayun Liang, Sheng‐You Huang, Salman M. Hyder, Xiaoqin Zou · 2011 · Journal of Molecular Graphics and Modelling
  91. Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
    Hsin‐An Hou, Hwei‐Fang Tien · 2020 · Journal of Biomedical Science
  92. A Natural Small Molecule Harmine Inhibits Angiogenesis and Suppresses Tumour Growth through Activation of p53 in Endothelial Cells
    Fujun Dai, Yihua Chen, Yajuan Song, Li Huang, Dong Zhai, Yanmin Dong, Li Lai, Tao Zhang, Dali Li, Xiufeng Pang et al. · 2012 · PLoS ONE
  93. Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1 MET
    Ruby Shalom‐Feuerstein, Laura Serror, Édith Aberdam, Franz-Josef Müller, Hans van Bokhoven, Klas G. Wiman, Huiqing Zhou, Daniel Aberdam, Isabelle Petit · 2013 · Proceedings of the National Academy of Sciences
  94. Targeting transcription factors by small compounds—Current strategies and future implications
    Judith Hagenbuchner, Michael J. Ausserlechner · 2015 · Biochemical Pharmacology
  95. Escape from immune- and nonimmune-mediated tumor surveillance
    Karl‐Johan Malmberg, Hans‐Gustaf Ljunggren · 2005 · Seminars in Cancer Biology
  96. Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
    Haffo, Lena, Lu, Jun, Bykov, Vladimir J. N., Martin, Sebastin S., Ren, Xiaoyuan, Coppo, Lucia, Wiman, Klas G., Holmgren, Arne · 2018 · Scientific Reports
  97. Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11
    Jacqueline E. Noll, Jessie Jeffery, Fares Al‐Ejeh, Raman Kumar, Kum Kum Khanna, David Frederick Callen, Paul Matthew Neilsen · 2011 · Oncogene
  98. 30 years and a long way into p53 research
    Pierre L. Hainaut, Klas G. Wiman · 2009 · The Lancet Oncology
  99. Functional protein microarrays for parallel characterisation of p53 mutants
    Jonathan M. Boutell, Darren J. Hart, Benjamin L. J. Godber, Roland Z. Kozlowski, Jonathan Michael Blackburn · 2004 · PROTEOMICS
  100. Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): implications to the therapy of pancreatic adenocarcinoma
    Demetrius M. Kokkinakis, Xiaoyan Liu, Russell Neuner · 2005 · Molecular Cancer Therapeutics